Regulus Therapeutics Inc (NASDAQ: RGLS) open the trading on Wednesday, with great promise as it jumped 11.28% to $1.48, before settling in for the price of $1.33 at the close. Taking a more long-term approach, RGLS posted a 52-week range of $0.83-$3.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -13.39%. Meanwhile, its Annual Earning per share during the time was 50.96%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 46.10%. This publicly-traded company’s shares outstanding now amounts to $65.50 million, simultaneously with a float of $52.59 million. The organization now has a market capitalization sitting at $96.95 million. At the time of writing, stock’s 50-day Moving Average stood at $1.3007, while the 200-day Moving Average is $1.6028.
Regulus Therapeutics Inc (RGLS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Regulus Therapeutics Inc’s current insider ownership accounts for 19.71%, in contrast to 64.41% institutional ownership. According to the most recent insider trade that took place on Jan 30 ’25, this organization’s Chief Executive Officer bought 50,000 shares at the rate of 1.09, making the entire transaction reach 54,260 in total value, affecting insider ownership by 260,808. Preceding that transaction, on Jan 30 ’25, Company’s Director bought 19,610 for 1.06, making the whole transaction’s value amount to 20,787. This particular insider is now the holder of 22,169 in total.
Regulus Therapeutics Inc (RGLS) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
Regulus Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 46.10% and is forecasted to reach -1.24 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -0.36% through the next 5 years, which can be compared against the 50.96% growth it accomplished over the previous five years trading on the market.
Regulus Therapeutics Inc (NASDAQ: RGLS) Trading Performance Indicators
Let’s observe the current performance indicators for Regulus Therapeutics Inc (RGLS). It’s Quick Ratio in the last reported quarter now stands at 13.65. The Stock has managed to achieve an average true range (ATR) of 0.12.
In the same vein, RGLS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.08, a figure that is expected to reach -0.21 in the next quarter, and analysts are predicting that it will be -1.24 at the market close of one year from today.
Technical Analysis of Regulus Therapeutics Inc (RGLS)
[Regulus Therapeutics Inc, RGLS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 68.77% While, its Average True Range was 0.1127.
Raw Stochastic average of Regulus Therapeutics Inc (RGLS) in the period of the previous 100 days is set at 69.15%, which indicates a major fall in contrast to 96.30% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 80.96% that was higher than 78.07% volatility it exhibited in the past 100-days period.
